Puma Biotechnology | PBYI - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amgen USD 2.08B 570M 2026-03
Biogen USD 647.3M 269.6M 2026-06
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Daiichi Sankyo JPY -6.52B 113.25B 2026-03
Exelixis USD 262.68M 5.01M 2026-06
Gilead Sciences USD -7.53B 10.11B 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 751.51M 407.91M 2026-06
MacroGenics USD -36.77M 21.84M 2026-03
Moderna USD -1.33B 535M 2026-03
Novartis USD 4.27B 430M 2026-06
Pfizer USD -653M 5.84B 2026-06
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Roche Holding CHF 11.17B 6.38B 2026-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
Takeda JPY 162.72B 215.2B 2026-06
TG Therapeutics USD 10.23M 10.13M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06